Thomson Geer is advising QBiotics Limited on its proposed $75m capital raise which it is undertaking via a numerous placements and prospectus offering. $50m of the raise has already been completed via a placement to TDM (see AFR article), remaining will be raised from sophisticated and professional investors and under a prospectus.

QBiotics Limited is an Australian biosciences company developing anti-cancer and wound healing drugs for humans and animals. It's anti-cancer drug is currently approved in the US for veterinary use (in dogs).

The transaction is valued at AUD$75m and the client intents to IPO in 2022.

The Thomson Geer team advising includes partner Ebru Davidson, partner Roberta Bozzoli, senior associate Venkatesh Ananthakrishnan and associate Catherine Wei.